Zinc Oxide
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
Zinc Oxide: Acne (disease)
One-Sentence Summary
Zinc oxide is a topical skin protectant originally used for conditions such as dermatitis, fungal skin infections, diaper-area irritation, hemorrhoids and burns. The TxGNN model predicts it may be effective for acne, but there are no registered clinical trials and only 3 publications (a review, a preclinical study and a small clinical study), so this remains a research question.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 0.9986 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs on record: at least 18; cancelled: 2) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, zinc oxide is a topical zinc preparation whose use in several inflammatory and irritated skin conditions is well established, and mechanistically it may be applicable to acne.
Zinc is generally thought to have antibacterial effects, including against Cutibacterium acnes, partly through zinc ion release and reactive oxygen species generation. It also has mild anti-inflammatory, sebum-regulating and astringent properties. Its existing use in dermatitis and other skin conditions suggests it is tolerated on the skin.
This link rests on general zinc biology, not on a documented drug-specific mechanism. The very high TxGNN score is a computational prediction only and does not replace clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15536660 | 2004 | Clinical study (small split-face) | Skin Res Technol | Assessment of mild inflammatory catamenial acne. Zinc compounds may be among the topical product’s ingredients, which would need confirming from the full text. |
| 21342155 | 2011 | Review | Int J Dermatol | Engineered nanoparticles such as zinc oxide and titanium dioxide are used in skin care products. Nano-preparations are under investigation for acne vulgaris and other skin conditions. |
| 36888703 | 2023 | Preclinical | Sci Adv | Ultrasound-responsive microneedle patch with zinc porphyrin-based nanoparticles for bacterial acne in a model. This is a different zinc-based material, not zinc oxide itself. |
Canada Market Information
Dosage forms and approved indication texts are not available for these products. The main ones are:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02239162 | ZINCOFAX | Not specified | Not specified |
| 02239160 | ZINCOFAX EXTRA STRENGTH | Not specified | Not specified |
| 02337452 | DIAPER RASH CREAM | Not specified | Not specified |
| 02455463 | MEDLINE REMEDY ESSENTIALS PROTECTANT PASTE | Not specified | Not specified |
| 02315793 | BAZA PROTECT II | Not specified | Not specified |
The remaining authorizations are mostly sunscreens and skin-care products (for example, ELTAMD UV products, OLAY SENSITIVE and COPPERTONE sunscreen stick).
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): The model’s drug-disease contraindication links include hypertension, benign prostatic hyperplasia, sickle cell anemia, primary hyperoxaluria, hereditary hemochromatosis, hemosiderosis, iron metabolism disease, Wilson disease, coronary artery disease, sudden cardiac arrest, heart conduction disease, hyperthyroidism, Graves disease, thyrotoxicosis and anxiety. These are model-derived links and are unlikely to reflect topical use directly. They should be checked against the official labels.
- Drug Interactions: No interaction records were found.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The acne prediction has a high model score but no registered clinical trials, and the only supporting literature is a review, a preclinical study and a small clinical study. The mechanistic link relies on general zinc biology. The other four predictions (anorectal stricture, anal polyp, papillary conjunctivitis, postinfectious vasculitis) have no supporting evidence at all and are weaker still.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada, so safety screening can proceed
- Mechanism of action data for zinc oxide (for example, from DrugBank)
- Confirmation of whether the 2004 split-face study actually tested zinc oxide
- Controlled clinical studies of topical zinc oxide in acne, with a defined formulation and concentration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.